References
- Atta MG, Fine DM. Editorial comment: tenofovir nephrotoxicity-the
disconnect between clinical trials and real-world practice. AIDS Read. 2009;
19:118-119. Google
Scholar
- Terrier Benjamin, Cacoub Patrice. Virus de l'hépatite
B, manifestations extrahépatiques immunologiques et risque de réactivation
virale. Revue de Médecine Interne. 2011; 32(10): 622-627. Google
Scholar
- Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002; 40: 1331-1333. PubMed | Google Scholar
- European Association for the Study of the Liver (EASL
2017). Clinical practice guideline on the management of Hepatitis B virus infection.
Journal of Hepatology. 2017; 67(2):370-398. Google
Scholar
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD
Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management
of Chronic Kidney Disease. Kidney inter. 2013; 3(Suppl): 1-150.
- Faye M, Ka EHF, Lemrabott AT et al. Prévalence
de la maladie rénale dans une zone semi-urbaine du Sénégal: résultats d'une
enquête transversale à la commune de GUEOUL. Communications affichées/Néphrologie
et thérapeutique. 2014;10(5): 391-401. Google
Scholar
- Amet S, Launay-Vachera V, Polb S et al. Prévalence des anomalies rénales dans l'hépatite B chronique : résultats de l'étude HARPE. Communications affichées / Néphrologie & Thérapeutique. 2012; 8(AE35): 390-413.
- Shin JH, Kwon HJ, Jang HR et al. Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine. 2016; 95(1): 1-10. PubMed | Google Scholar
- Lord A, Ménard C. La néphrotoxicité médicamenteuse. Le Médecin du Québec. 2002; 7(6):55-59.
- Thu AM, Poovorawan K, Kittitrakul C et al. Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. BMC Pharmacology and Toxicology. 2015; 16:1-9. PubMed | Google Scholar
- Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez
GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease
and death. Am J Med. 2009; 122(7): 672-678. PubMed | Google
Scholar
- Brahimi M, Lesperres B. Rein et facteurs de risque. Correspondances en risque CardioVasculaire. 2004; 2(4): 163-165.
- Gara N, Zhao X, Collins MT et al. Renal tubular
dysfunction during long term adefovir or tenofovir therapy in chronic hepatitis
B. Aliment Pharmacol Ther. 2012; 35(11): 1317-1325. Google
Scholar
- Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012; 10(8): 941-946. PubMed | Google Scholar
- Basit SA, Dawood A, Ryan J, Gish R. Tenofovir alafenamide
for the treatment of chronic hepatitis B virus infection. Expert Review Of
Clinical Pharmacology. 2017; 10(7): 707-716. Google
Scholar